Australia Won't Rush Pfizer After Homegrown Vaccine Canned

University of Queensland (UQ) virologist Dr Kirsty Short said the setback should not be surprising.

"Rather, the vaccine's signature "molecular clamp" technology was formulated with parts of an HIV protein".

"The fact the problem has arisen is not surprising". "People had sacrificed a lot this year", he said.

There was a huge rush for developing vaccines with the sudden occurrence of the Coronavirus.

Dr Short said the journey was not over for the UQ vaccine candidate just yet.

The vaccine was being developed by Australian firm CSL and the University of Queensland, and fixing the error would have taken a year of research - prompting its backers to pull the plug.

"This is not the last pandemic that we will experience, so we still need technology classes to be developed".

The vaccine had been in stage one of trials, and proving to be effective in making antibodies. But "it was unexpected that the levels induced would interfere with certain HIV tests", reads a joint statement announcing the halt of the candidate's development that was posted online by UQ and CSL. Nearly all the countries in the world were doing their contribution to the sooner development of the vaccine.

He said this was the "right call".

Upon the announcement, AstraZeneca added that it would begin preparing a regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval.

The government said it had prepared for this sort of situation and as such had "spread the risk" with multiple deals for vaccines.

Dr Symons said the cancellation's "silver lining" was that it could boost public perception of the vaccine development process.

Morrison says he wants Australians to have "absolute full confidence that when it gets the tick, they can get the jab".

"This is the evidence the Government is showing appropriate concern for safety and for ensuring that vaccines that are brought to market are actually engaged, safe, and are not going to have unintended effects on other aspects of healthcare in Australia".

It's understood the clinical trial of this vaccine candidate is not stopping but the future development of the vaccine will not proceed.

What won't continue is the large scale trials that would measure the efficacy of the particular vaccine, ruling it out as a possible cure to be rolled out nation-wide.

"It's just such a bad shame that it's ending this way, but I would do it again in a heartbeat", she said.

But it also generated HIV antibodies in some recipients - which meant it showed false positives for HIV. What's more, officials anxious that false positives might undermine the public's faith in the vaccine. So that's why this has stopped, " Clinical epidemiologist at the Melbourne School of Population and Global Health, Nancy Baxter told the Australian Broadcasting Corporation. "I think today, and the decisions we've taken should give Australians great assurance, that we are proceeding carefully, we are moving swiftly, but not with any undue haste here". It means that subject to the results of those trials, the vaccine would get available potentially for delivery early in the third quarter of 2021 to the Australians.